Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Syncona

- PMLiVE

Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer

The approval for the treatment applies to England, Scotland and Wales

- PMLiVE

FDA approves Bot Image’s AI software for the detection and diagnosis of prostate cancer

ProstateID combines artificial intelligence with traditional MRI scanning to significantly improve radiologic interpretation accuracy

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape

Joshua Yang, Co-founder & CEO of Glyphic Biotechnologies and Co-founder of NephroSant, dives into next-generation protein sequencing for biomedical research and clinical medicine, his journey from academia to entrepreneurship, and...

Impetus Digital

- PMLiVE

Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

mCRPC patients treated with Lu-PSMA-617 plus best standard of care achieved a 38% reduction in the risk of death

Nanobiotechnology, Artificial Intelligence, and Virtual Care

Venk Varadan, Co-founder & CEO at Nanowear, explores the use of cloth-based nanosensor technology, AI, and deep-learning-enabled diagnostics for remote monitoring of congestive heart failure, chronic diseases, and COVID-19. We...

Impetus Digital

- PMLiVE

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Decision follows mixed results from the phase 3 ACIS study

- PMLiVE

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Therapy hit both primary endpoints of overall survival and radiographic progression-free survival

- PMLiVE

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Final analysis demonstrates a 35% reduction in the risk of death in mHSPC patients

- PMLiVE

FDA approves Myovant’s oral pill Orgovyx for prostate cancer

This is a new option for advanced prostate cancer patients in the US

- PMLiVE

AZ/Merck’s Lynparza improves survival in certain prostate cancers

New data released at ESMO 2020 virtual congress shows drug cuts the risk of death

Impetus Digital Fireside Chat With Richie Bavasso From NqMedical

Richie Bavasso, founder and CEO of nQMedical, discusses everything from digital therapeutics, diagnostics, and other data-driven solutions for neurodegenerative diseases to Richie’s favorite media outlets, his work at nQMedical, and lessons learned...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links